



Pfenex to Participate at Two Investor Conferences in March

SAN DIEGO, February 27, 2019—Pfenex Inc. (NYSE American: PFXN) a clinical-stage development and licensing biotechnology company focused on leveraging its *Pfēnex* Expression Technology® to improve protein therapies for unmet patient needs, announced today that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Barclays Global Healthcare Conference, taking place March 12-14 in Miami, Florida, and participating at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking March 19-20 in New York City.

Barclays Global Healthcare Conference

Date: Wednesday, March 13

Time: 4:20pm Eastern Time

Oppenheimer & Co. 29th Annual Healthcare Conference

Date: Tuesday, March 19

Format: One-on-One Meetings

Interested parties can access the live audio webcast and archive for the Barclays Global Healthcare Conference presentation from the Investors Section of Pfenex's website at www.pfenex.com.

About Pfenex Inc.

We are a clinical-stage development and licensing biotechnology company focused on leveraging our *Pfēnex* Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented *Pfēnex* Expression Technology platform, we have created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company also uses its *Pfēnex* Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccines. Our lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and our novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, we are developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (<http://www.pfenex.com/>), our investor relations website (<http://pfenex.investorroom.com/>), press releases, SEC filings, public conference calls, corporate Twitter account (<https://twitter.com/pfenex>), Facebook page (<https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/>), and LinkedIn page

(<https://www.linkedin.com/company/pfenex-inc>) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Company Contact:

Susan A. Knudson

Chief Financial Officer

(858) 352-4324

sknudson@pfenex.com